Tradestie Institutional Equity Comparison Engine

IONS vs ARWR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ARWR Overall Edge

ARWR Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arrowhead Research Corporation (ARWR) driven by superior Growth & Margin, Momentum & Technical while IONS counters with relative strength in Valuation, Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus ARWR at 111.1x Forward P/E and -33.8% operating margin (+171.0% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against ARWR sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IONS
IONS 90.9x vs ARWR 111.1x Fwd P/E
Growth & Margin Winner ARWR
Op Margin -58.8% vs -33.8% ยท YoY +54.9% vs +171.0%
Momentum & Technical Winner ARWR
1Y -59.1% vs +8.3% ยท 52W Pos 2% vs 13%
Options & Structure Winner IONS
BREAKDOWN (17th %ile IV) vs BREAKDOWN (15th %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
ARWR NASDAQ
Arrowhead Research Corporation
Pharmaceutical Preparations
$44.57
-6.72% 1D
Market Cap $6.7B
1M Return -20.27%
1Y Return +8.34%
Forward P/E 111.1x
Unified AI Score
45.1 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 66.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% ARWR +8.34% Spread: +67.44 pp (ARWR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IONS Revenue ARWR Revenue IONS Op. Margin ARWR Op. Margin Margin Edge
FY2019 $1.12B $170M 32.6% 36.3% ARWR
FY2020 $730M $90M -23.6% -105.9% IONS
FY2021 $810M $140M -3.7% -107.8% IONS
FY2022 $590M $240M -69.8% -73.4% IONS
FY2023 $790M $240M -44.9% -85.2% IONS
FY2024 $710M $0M -67.4% -16927.1% IONS
FY2025 $940M $830M -40.4% 11.9% ARWR
FY2026 N/A $450M N/A -156.9% ARWR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (3) vs ARWR (7)
Institutional Metric IONS ARWR Criterion Row Winner
Market Capitalization Scale $4.7B $6.7B Larger Scale ARWR
Trailing P/E Ratio Valuation 90.9x 111.1x Lower Multiple IONS
Forward P/E Ratio Valuation 90.9x 111.1x Lower Multiple IONS
Revenue Growth (YoY) Growth +54.9% +171.0% Higher Growth ARWR
Operating Margin (TTM) Profitability -58.8% -33.8% Higher Margin ARWR
Net Profit Margin Profitability -56.9% -47.8% Higher Margin ARWR
Return on Equity (ROE) Capital Efficiency -108.0% -55.2% Higher ROE ARWR
52-Week Range Position Momentum 2% ($27โ€“$87) 13% ($37โ€“$95) Stronger Trend ARWR
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 1.34ฮฒ ยท 66% Vol Lower Realized Risk ARWR
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 45.1 / 100 (HOLD) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs ARWR Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARWR BREAKDOWN
128d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 15th %ile
IV Regime Compressed (<25th %ile)
Live ARWR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor ARWR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.